Close
Important Safety Information You Should Know About CIMZIA® (certolizumab pegol). Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated for use in pediatric patients. ©2024 UCB, Inc., 1950 Lake Park Drive, Smyrna, GA 30080. All rights reserved. CIMZIA® is a registered trademark of the UCB Group of Companies. US-CZ-2400268 Click to open or close full safety information Prescribing Information.
